2021
Chapter 15 Positron emission tomography imaging agents for evaluating the pathologic features of Alzheimer's disease and drug development
Huang Y, Jia H, Bao W. Chapter 15 Positron emission tomography imaging agents for evaluating the pathologic features of Alzheimer's disease and drug development. 2021, 367-412. DOI: 10.1016/b978-0-12-816475-4.00013-6.Peer-Reviewed Original ResearchAlzheimer's diseasePathologic featuresApplication of PETDrug developmentSynaptic vesicle protein 2ADifferent pathologic featuresFeatures of neurodegenerationCentral nervous systemAD drug developmentPositron emission tomographyNeuroinflammation biomarkersCholinergic systemΒ-amyloidNervous systemTau proteinEmission tomographyAD researchDiseaseProtein 2AInvestigation of diseasesQuantitative imaging techniquesTomographyImaging techniquesAgentsPET
2001
Imaging Human Mesolimbic Dopamine Transmission With Positron Emission Tomography: I. Accuracy and Precision of D2 Receptor Parameter Measurements in Ventral Striatum
Mawlawi O, Martinez D, Slifstein M, Broft A, Chatterjee R, Hwang D, Huang Y, Simpson N, Ngo K, Van Heertum R, Laruelle M. Imaging Human Mesolimbic Dopamine Transmission With Positron Emission Tomography: I. Accuracy and Precision of D2 Receptor Parameter Measurements in Ventral Striatum. Cerebrovascular And Brain Metabolism Reviews 2001, 21: 1034-1057. PMID: 11524609, DOI: 10.1097/00004647-200109000-00002.Peer-Reviewed Original ResearchConceptsPositron emission tomographyVentral striatumDopamine transmissionReceptor measurementsEmission tomographyMesolimbic dopamine transmissionHigh-resolution magnetic resonanceNonspecific partition coefficientDrugs of abuseDorsal putamenPostmortem studiesVentral putamenDorsal caudateVentral caudateNucleus accumbensConstant infusion methodReceptor availabilityPsychotic statesStriatumReceptorsPutamenCaudateSpecific bindingInfusion methodTomography